Maze Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 12, 2026
MAZE$34.91+2.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Quarterly Report on Form 10-Q to be signed on its behalf by the undersigned, thereunto duly authorized.
| MAZE THERAPEUTICS, INC. | ||
| Date: May 12, 2026 | By: | /s/ Jason Coloma |
|---|---|---|
| Jason Coloma | ||
| Chief Executive Officer(Principal Executive Officer) | ||
| MAZE THERAPEUTICS, INC. | ||
| Date: May 12, 2026 | By: | /s/ Misbah Tahir |
|---|---|---|
| Misbah Tahir | ||
| Chief Financial Officer(Principal Financial Officer) | ||
| MAZE THERAPEUTICS, INC. | ||
| Date: May 12, 2026 | By: | /s/ Amy Bachrodt |
|---|---|---|
| Amy Bachrodt | ||
| Senior Vice President, Finance(Principal Accounting Officer) | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.